PST-674 / Pharmasum Therap - LARVOL DELTA

PST-674 IS A NOVEL, HIGHLY POTENT AND SELECTIVE DYRK1A KINASE INHIBITOR (ADPD 2023) - "We have designed PST -674 as a potent DYRK1A kinase inhibitior using structure -based drug discovery and lead optimization efforts. PST -674 is highly selective and shows excellent drug -like characteristics allowing it to progress to further development."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders • Genetic Disorders • Immunology • Inflammation • Mental Retardation • Movement Disorders • Parkinson's Disease

DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer's Disease-Down Syndrome Phenotypes. (PubMed, Front Pharmacol) - "PST-001 reduced degeneration caused by human Tau, Amyloid-β or mnb lengthening lifespan as well as improving locomotion, sleep and memory loss caused by expression of these AD and DS genes. This demonstrated PST-001 effectiveness as a potential new therapeutic targeting AD and DS pathology."

Journal • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders • APP • MAPT

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome. (PubMed, Pharmaceuticals (Basel)) - "The present study introduces a novel inhibitor for the protein kinase DYRK1A, a key controlling kinase whose encoding gene is located on chromosome 21. The novel inhibitor is well characterized for use in mouse models and thus represents a valuable tool compound for further DYRK1A research."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation